A Pilot Evaluation of the Pharmacokinetics, Efficacy and Safety of Switching From Efavirenz to Maraviroc Administered at 600mg Then 300mg Twice-daily in Patients Suppressed on an Efavirenz-containing Regimen as Initial Therapy.
Phase of Trial: Phase IV
Latest Information Update: 02 May 2012
At a glance
- Drugs Maraviroc (Primary)
- Indications HIV-1 infections
- Focus Pharmacogenomic; Pharmacokinetics
- 07 Jun 2017 Biomarkers information updated
- 11 Apr 2012 Actual end date (March 2012) added as reported by ClinicalTrials.gov.
- 11 Apr 2012 Actual patient number added 12 according to ClinicalTrials.gov.